Nivolumab Maintenance as Monotherapy after Carboplatin Plus Nab-Paclitaxel for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Study Protocol for Feasibility

Masao Ichiki1, Ken Masuda1, Chiyo Yano1, Yusuke Okayama1, Hanako Oda1, Yohei Imamura1, Hiroaki Takeoka1 and Tomoaki Hoshino2

1Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka City, Fukuoka, Japan
2Division of Respiriology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University, Kurume City, Fukuoka, Japan

Corresponding author: Masao Ichiki, Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka City, Fukuoka, Japan, Tel: +81-92-852-0700; E-mail: ichiki@kyumed.jp

Received date: August 29, 2017; Accepted date: September 15, 2017; Published date: September 18, 2017

Abstract

The aim of this study is to determine the feasibility of nivolumab as maintenance therapy after first-line chemotherapy with carboplatin plus nab-paclitaxel in non-small-cell lung cancer. Since we cannot change the dose of nivolumab, we will investigate the recommended doses and cycles of pretreatment chemotherapy with carboplatin plus nab-paclitaxel that affect maintenance therapy. The primary endpoint is incidence of any grade ≥ 3 adverse events during the first 12 weeks of nivolumab treatment. Twelve patients are required in this study.

Keywords: Maintenance therapy; Nivolumab; Non-small-cell lung cancer; Study protocol

Introduction

Nivolumab, a fully Immunoglobulin G4 (IgG4) programmed death-1 antibody, has demonstrated activity and tolerability in previously treated advanced non-small-cell lung cancer (NSCLC) [1]. A significant improvement in overall survival (OS) with nivolumab was observed in squamous NSCLC patients in the CheckMate 017 trial (nivolumab versus docetaxel) and in non-squamous NSCLC patients in the CheckMate 057 trial (nivolumab versus docetaxel) [2,3]. Nivolumab was also associated with longer progression-free survival (PFS) compared with docetaxel in the CheckMate 017 trial. In the study of nivolumab in combination with platinum-based doublet chemotherapy in NSCLC, it has been reported that the safe profile of nivolumab and platinum-based chemotherapy was consistent with what would be expected for individual drugs [4]. However, treatment-related adverse events led to discontinuation in 21% of patients, and discontinuation of treatment associated with adverse events was higher with combination therapy [4].

The safety and efficacy of pemetrexed and bevacizumab have been proven as maintenance therapy for non-squamous NSCLC. Continued maintenance therapy with pemetrexed after induction therapy with cisplatin plus pemetrexed significantly improved PFS and OS compared with placebo therapy for non-squamous NSCLC, and switching to maintenance therapy with pemetrexed after platinum-based doublet chemotherapy also improved PFS and OS [5,6]. Continued maintenance therapy with bevacizumab after carboplatin plus paclitaxel had a significant survival benefit compared with carboplatin plus paclitaxel alone therapy [7]. Nab-paclitaxel as maintenance therapy after carboplatin plus nab-paclitaxel in squamous NSCLC is under clinical trial [8]. Maintenance therapy after first-line chemotherapy is being established as a common treatment for both non-squamous and squamous NSCLC.

Based on these considerations, we conducted a feasibility study of nivolumab as maintenance therapy after first-line chemotherapy with carboplatin plus nab-paclitaxel for NSCLC.

Protocol of the Study

Objective

The study is a feasibility study that is designed to demonstrate the safety and efficacy of maintenance nivolumab monotherapy administered to patients with advanced NSCLC who showed clinical benefit from first-line chemotherapy with carboplatin plus nab-paclitaxel.

Endpoints

The primary endpoint is determination of the optimal doses and cycles of first-line chemotherapy with carboplatin plus nab-paclitaxel in accordance with the incidence of any grade ≥ 3 events during the first 12 weeks of nivolumab treatment. The secondary endpoints are response rate, disease control rate, PFS, and OS.

Eligibility Criteria

Inclusion criteria

The inclusion criteria are:

- Histologically or cytologically confirmed NSCLC
- No prior treatment
- Stage IIIIB, IV and unsuitable for thoracic radiotherapy
- Tested negative for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation
- Tumor programmed death ligands 1 (PD-L1) expression levels of 1–49%
One or more measurable disease
Eastern Cooperative Oncology Group-performance status of 0 to 1
Aged 20–79 yrs at the time of registration
Adequate function of vital organs, as evaluated within 7 days before registration
Hematopoietic function
White blood cells ≥ 3000/mm³
Neutrophils ≥ 1500/mm³
Platelets ≥ 100,000/mm³
Hemoglobin ≥ 9.0 g/dL
Liver function
Total bilirubin ≤ 1.5 mg/dL
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2 times the normal upper limit
Renal function
Creatinine clearance ≥ 60 ml/min
Life expectancy of at least 3 months
Able to provide written informed consent before registration

Exclusion criteria
The exclusion criteria are:
- Intestinal pneumonia or pulmonary fibrosis on chest X-ray
- Patients who have received chest radiation therapy
- Auto-immune disease patients
- Patients who have received systemic steroid therapy
- Symptomatic brain metastasis
- Active hepatic disease
- Serious complications (heart failure, renal failure, severe liver dysfunction, gastric ulcer with bleeding, ileus, bowel obstruction, uncontrolled diabetes)
- Uncontrolled ascites, pleural effusion, and cardiac effusion
- History of multiple malignancies within 3 years
- Planning of surgery during the trial
- Pregnant or nursing women with the possibility (intention) of the pregnancy
- Serious mental disorders
- Previous drug allergy
- Patients are judged to be unsuitable by the attending physician

Registration
An eligible report form will be sent to the registration center at the Clinical Research Institute of Kyushu Medical Center. Information on necessary follow-up tests will then be sent from the registration center.

Study Design
This study is being conducted in accordance with the Declaration of Helsinki and is registered with the University Hospital Medical Information Network in Japan, number UMIN000027985. The research protocol was approved by the ethics committee of Kyushu Medical Center (registration number 17A105).

Treatment plan and evaluation
According to the study of nivolumab in combination with platinum-based chemotherapy, it has been reported that 45% of patients had grade 3 or 4 treatment-related adverse events [4]. Therefore, we stipulated that induction chemotherapy is unacceptable if nivolumab maintenance monotherapy has an incidence of more than 45% for grade 3 or 4 adverse events. If three or more of the first six patients who had been originally allocated to level 1 experience nivolumab-induced grade 3–4 toxicity, an additional six patients will be enrolled to level 0. (Level 1, carboplatin at an area under the concentration time curve (AUC) 6 mg/ml/min on day 1+nab-paclitaxel 100 mg/m² on days 1, 8, and 15 with treatment cycles repeated every 3 weeks for a planned maximum of four cycles; Level 0, carboplatin AUC 5 mg/ml/min on day 1+nab-paclitaxel 100 mg/m² on days 1, 8, and 15 with treatment cycles repeated every 3 weeks for a planned maximum of three cycles). If two or less of the first six patients in level 1 experience nivolumab-induced grade 3–4 toxicity, an additional six patients will be enrolled to level 1. We will evaluate optimal doses and cycles of first-line chemotherapy with carboplatin plus nab-paclitaxel for a phase II study. The investigator will evaluate the grade of any adverse events before, during (until first 12 weeks), and after nivolumab monotherapy. In addition, the decision to administer nivolumab monotherapy will be made within 3–5 weeks after the end of first-line chemotherapy with carboplatin plus nab-paclitaxel. Evaluations of toxicity are based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI-CTCAE v4.0). Tumor response is also evaluated every month by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria against the target lesion.

Confidentiality
Clinical data is used for research purposes only. Results are kept anonymous and safe.

Conflict of Interest
There is no conflict of interest to report for the researchers concerning this study.

References
1. Brahmner JR, Drake CG, Wöller L, Powderly JD, Picus J, et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
2. Brahmner J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, et al. (2015) Nivolumab vs. Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373: 123-135.
3. Borgheai E, Par-Ares L, Horn L, Spigel DR, Steins M, et al. (2015) Nivolumab vs. Docetaxel in Advanced Non-squamous Non-Small-Cell Lung Cancer. N Engl J Med 373: 1627-1639.
4. Rizevi NA, Hellmann MD, Brahmner JR, Juergens RA, Borgheai H, et al. (2016) Nivolumab in Combination With Platinum-Based Doublet
Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 34: 2969-2979.

5. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Puiol JL, et al. (2012) Maintenance therapy with pemetrexed plus best supportive care vs. placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13: 247-255.

6. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, et al. (2009) Maintenance pemetrexed plus best supportive care vs. placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440.

7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.

8. Kellerman A. A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC). NCT02027428.